A validated risk model for overall survival in relapsed/refractory chronic lymphocytic leukemia applicable to patients treated with novel therapies and standard of care Meeting Abstract
| Authors: | Soumerai, J. D.; Ni, A.; Darif, M.; Londhe, A.; Xing, G.; Huang, J.; Lin, M.; Byrd, J. C.; Chanan-Khan, A. A.; Furman, R. R.; Hallek, M.; Hillmen, P.; Jones, J.; Sharman, J. P.; Ferrante, L.; Reddy, V.; Dreiling, L. K.; Adewoye, H.; Dubowy, R.; Howes, A.; James, D. F.; Zelenetz, A. D. |
| Abstract Title: | A validated risk model for overall survival in relapsed/refractory chronic lymphocytic leukemia applicable to patients treated with novel therapies and standard of care |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419703313 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.4303.4303 |
| Notes: | Meeting Abstract: 4303 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
